logo

BALPHARMA vs SANOFI: Stock Comparison

BALPHARMA vs SANOFI INDIAUpdated 5 Oct 26, 4:08 PM ISTNSE & company filings

SANOFI INDIA is the larger company by market capitalisation. BALPHARMA shows faster revenue growth, while SANOFI INDIA shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

BALPHARMA leads 1; SANOFI leads 8 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

BALPHARMASANOFI

Valuation lens

What price are you paying?

Market CapContext only
₹134 Cr
₹6,529 Cr
P/E RatioSame reading
—
0x
P/B RatioSame reading
—
0x
EPSSANOFI has the higher reading
₹0.71
₹39.64 ✓
Book ValueContext only
₹51.66
₹325.31
Dividend YieldSANOFI has the higher reading
1.36%
4.36% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SANOFI is the larger company
₹6,529 Cr vs ₹134 Cr
EPS
SANOFI has higher earnings per share
₹39.64 vs ₹0.71
Dividend Yield
SANOFI has a higher dividend yield
4.36% vs 1.36%
Revenue Growth (TTM YoY)
BALPHARMA has faster revenue growth
2.7% vs -11.9%
EPS Growth (TTM YoY)
SANOFI has faster EPS growth
-14.1% vs -33.5%
ROE
SANOFI has a higher ROE
41.35% vs 6.49%
ROCE
SANOFI has a higher ROCE
64.11% vs 9.07%
Net Margin
SANOFI has a higher net margin
19.26% vs 2.02%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBALPHARMASANOFI
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBALPHARMASANOFI
Live Price₹106.79₹2,831.1
Day Change0.99%0.13%
Volume25,52215,277
52-Week High₹124.6₹4,898
52-Week Low₹60₹2,820.1
Distance from 52W High-14.29%-42.2%

Valuation

MetricBALPHARMASANOFI
Market Cap₹134 Cr₹6,529 Cr
P/E Ratio—0x
P/B Ratio—0x
EPS₹0.71₹39.64
Book Value₹51.66₹325.31
Dividend Yield1.36%4.36%

Growth

MetricBALPHARMASANOFI
Revenue Growth (TTM YoY)2.7%-11.9%
EPS Growth (TTM YoY)-33.5%-14.1%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricBALPHARMASANOFI
ROE6.49%41.35%
ROCE9.07%64.11%
Net Margin2.02%19.26%
Operating Margin7.46%23.62%
Debt to Equity1.48x0x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricBALPHARMASANOFI
Promoter Holding46.74%0%
FII Holding0.28%▲ 0.13 pp5.69%▲ 0.05 pp
DII Holding0%19.87%▼ 1.26 pp
Public Holding48.87%▼ 0.12 pp14.04%▲ 1.21 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BALPHARMA and SANOFI INDIA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.